Johnson John Paul
Known title: Chief Financial OfficerCIK: 0001782040
Associated companies
Transaction History
| EVH | ▲ Buy | Grant | 25,461 | $0 | 7/1/2025 | View on chart |
| EVH | ▲ Buy | Grant | 89,113 | $0 | 3/3/2025 | View on chart |
| EVH | ▲ Buy | Grant | 59,582 | $0 | 3/3/2025 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 26,872 | $236K | 3/3/2025 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 9,246 | $83K | 3/1/2025 | View on chart |
| EVH | ▼ Sell | Open Market | 44,693 | $1.3M | 8/22/2024 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 9,020 | $310K | 3/2/2024 | View on chart |
| EVH | ▲ Buy | Grant | 12,123 | $0 | 3/1/2024 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 11,213 | $386K | 3/1/2024 | View on chart |
| EVH | ▲ Buy | Grant | 44,000 | $0 | 2/22/2024 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 20,006 | $661K | 2/22/2024 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 9,020 | $317K | 3/2/2023 | View on chart |
| EVH | ▲ Buy | Grant | 20,413 | $0 | 3/1/2023 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 3,681 | $130K | 3/1/2023 | View on chart |
| EVH | ▲ Buy | Grant | 44,000 | $0 | 2/21/2023 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 20,025 | $562K | 2/21/2023 | View on chart |
| EVH | ▼ Sell | Open Market | 18,434 | $629K | 8/17/2022 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 32,344 | $891K | 3/3/2022 | View on chart |
| EVH | ▲ Buy | Option Exercise | 71,716 | $0 | 3/2/2022 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 9,020 | $248K | 3/2/2022 | View on chart |
| EVH | ▲ Buy | Grant | 24,000 | $0 | 3/1/2022 | View on chart |
| EVH | ▼ Sell | Tax Withholding | 4,510 | $124K | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract
Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract. Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.